Novo Nordisk Aktie
40,32
EUR
-0,84
EUR
-2,03
%
40,20
EUR
-1,02
EUR
-2,47
%
Werbung
Novo Nordisk Aktie Analyse
| 07.08.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 31.07.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 19.07.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 12.07.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 11.07.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 11.07.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 10.07.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 04.07.24 | Novo Nordisk Buy | Deutsche Bank AG | |
|
Werbung
|
|||
| 03.07.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 27.06.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 27.06.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 25.06.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 24.06.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 20.06.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 14.06.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 30.05.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 28.05.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 24.05.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 14.05.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 07.05.24 | Novo Nordisk Overweight | Barclays Capital | |
| 03.05.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 03.05.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 02.05.24 | Novo Nordisk Overweight | Barclays Capital | |
| 02.05.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 13.09.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 08.09.23 | Novo Nordisk Overweight | Barclays Capital | |
| 07.09.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 05.09.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 04.09.23 | Novo Nordisk Overweight | Barclays Capital | |
| 25.08.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 21.08.23 | Novo Nordisk Overweight | Barclays Capital | |
| 15.08.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 11.08.23 | Novo Nordisk Overweight | Barclays Capital | |
| 11.08.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 10.08.23 | Novo Nordisk Overweight | Barclays Capital | |
| 10.08.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 09.08.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 08.08.23 | Novo Nordisk Overweight | Barclays Capital | |
| 08.08.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 03.08.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 03.08.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 27.07.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 12.07.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 11.07.23 | Novo Nordisk Outperform | Credit Suisse Group | |
| 03.07.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 29.06.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 28.06.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 27.06.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 26.06.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 23.05.23 | Novo Nordisk Overweight | Barclays Capital | |
Werbung
Werbung